WATERTOWN, Mass., Sept. 19, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that Enanta was named by FierceBiotech as one of 2012's Fierce 15.
The annual award, which was announced today during the BioPharm America Conference at the Westin Boston Waterfront Hotel in Boston, was created by FierceBiotech to recognize 15 promising private biotech companies selected from around the world for their potential to have impact on the treatment of human diseases. This is FierceBiotech's tenth annual Fierce 15 selection. Every year, FierceBiotech evaluates hundreds of private companies for the list, which is based on a variety of factors including the strength of each company's technology, partnerships, venture funding and a competitive market position.
"While biotechs have been scrambling in the race to the market with an interferon-free treatment for hepatitis C, Enanta has been building its pipeline of compounds for use in HCV combination therapies," said FierceBiotech Editor John Carroll. "It's struck key partnerships with Abbott and Novartis and has additional unpartnered programs."
"We are honored to be chosen as one of the Fierce 15 and recognized for our work in the infectious disease field—specifically, our work in multiple HCV drug classes designed for use against the hepatitis C virus," commented Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. "Our goal of providing patients with innovative therapies that are safer and more effective than current treatments is what motivates our employees every day."
About Enanta
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with Abbott), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, the company has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately-held company headquartered in Watertown, Massachusetts. Enanta's news releases and other information are available on the company's website at www.enanta.com.
About FierceBiotech
FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 100,000 top biotech and pharma professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at www.fiercebiotech.com.
Investor Contact
Carol Miceli
Enanta Pharmaceuticals, Inc.
617-607-0710
[email protected]
Media Contact
Kari Watson
MacDougall Biomedical Communications
781-235-3060
[email protected]
SOURCE Enanta Pharmaceuticals, Inc.